ANI Pharmaceuticals ANIP Brands — Net Revenues

Similar metrics at other companies

VTRSBrands — Net Sales

$2.33B+10.2%

HASGrow Brands — Net revenues

$787.5M+19.2%

BLCOBranded and Other Generics — Total revenues

$49M-9.3%

ARDXProduct sales, net — Total revenues

$93.37M+37.7%

BCRXProduct sales, net — Total revenues

$151.4M+5.3%

EXELNet product revenues — Total revenues

$554.98M+8.1%

Questions, answered.

What is ANI Pharmaceuticals's brands — net revenues?

ANI Pharmaceuticals (ANIP) reported brands — net revenues of $12.33M in Q1 2026.

How has ANI Pharmaceuticals's brands — net revenues changed year-over-year?

ANI Pharmaceuticals's brands — net revenues decreased by 50.9% year-over-year, from $25.12M to $12.33M.

What is the long-term trend for ANI Pharmaceuticals's brands — net revenues?

Over 3 years (2022 to 2025), ANI Pharmaceuticals's brands — net revenues has grown at a 15.8% compound annual growth rate (CAGR), from $39.46M to $61.31M.

What does brands — net revenues mean?

This metric represents the total net revenue generated from the sale of established branded pharmaceutical products within the company's portfolio. It reflects the market demand and pricing power of proprietary or acquired brand-name drugs as distinct from generic offerings. Monitoring this figure helps investors assess the stability and contribution of the company's branded product segment to overall corporate financial performance.